Concentrix reports fiscal Q3 results today carrying a stock that has shed 18% in a single week, into a market where short sellers are still pulling back even as options traders load up on downside protection.
The short-covering trend noted in the preview published four days ago has continued. Short interest has declined a further 8% over the past week to 13.5% of the free float, down from a peak near 17% in early September. Borrow availability has loosened further to 258%, up 45% on the week, meaning there are now more than two-and-a-half times as many shares available to borrow as there are already on loan. Cost to borrow remains low at 0.60%. The ORTEX short score has edged down to 65.3 from 66.5 at the time of the prior article, consistent with the same directional retreat. Bears are not pressing into this print, but the stock's 15% one-month decline means they may not need to.
Options positioning tells a different story. The put/call ratio has climbed further to 1.24, now running about 1.7 standard deviations above its 20-day average of 0.93. That is the most defensive options skew since the ratio briefly spiked last spring. Put demand has been building steadily since mid-September: the ratio was below 0.90 as recently as September 18 and has risen almost every session since. The prior quarter produced a 10% single-day drop in the stock, and that memory appears to be shaping how options traders are positioned today.
The bull-versus-bear debate on the stock is framed by a wide spread between the current price and analyst targets, though that gap requires context. After a cluster of target cuts following last quarter's print, the consensus now sits around $36, well above the $24.88 close. B of A Securities moved to a $26 target in late June while keeping a Neutral rating. Several other firms maintained positive ratings but cut targets by 20% to 30%. Those cuts are now three months old, and the stock has fallen further since. Two activist holders remain on the 13D register: Impactive Capital, last disclosed at 4.9%, and Groupe Bruxelles Lambert, which cut its stake from 14.24% to 4.55% in a 6-million-share open-market sale in late April at $22.25 per share, a transaction worth $133.5 million. That sale, which was not made under a 10b5-1 plan, represents the most significant insider-side activity in recent months and stands as a material signal of reduced conviction from a formerly large holder. Stakes on the 13D register are as last disclosed and positions can fall below 5% without a further filing.
The CEO purchased 1,000 shares in early July at $21.25, a modest open-market buy that at least signals some personal commitment at current levels. BlackRock lifted its stake to 10.9% as of August and FMR to 9.4%, providing some institutional ballast. The earnings print will test whether the business has stabilised enough to justify even the reduced consensus targets, or whether the pattern from last quarter repeats at a stock already trading near multi-year lows.
See the live data behind this article on ORTEX.
Open CNXC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
